Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NexGel Inc ( (NXGL) ) just unveiled an announcement.
On April 17, 2026, NEXGEL completed an amended asset purchase and exclusive license deal with Celularity to acquire an exclusive license to a commercial-stage regenerative biomaterials portfolio, related assets and sales representative obligations. The amendment set total consideration at $13.3 million, comprising an $8.3 million upfront cash payment and a $5 million 10% convertible note at a $0.60 conversion price, adjusted milestone timing, removed holdbacks and extended the transaction outside date to April 30, 2026.
To fund the transaction, on April 17, 2026 NEXGEL raised $6.9 million in gross proceeds via a private placement of unsecured 10% convertible notes and warrants to accredited investors, with capacity for up to an additional $475,000 on the same terms. The notes, including a parallel $5 million Celularity note, are convertible at $0.60 per share with anti-dilution protections and are paired with five-year warrants exercisable at $0.80, subject to ownership caps and an issuance limit tied to 19.99% of outstanding common stock unless shareholders approve more.
The financing included approximately $500,000 of Celularity sales representative obligations converted into notes and warrants, as well as a $125,000 participation by NEXGEL directors and executives on the same terms as other buyers. NEXGEL committed to seek shareholder approval to lift the exchange cap and to register the resale of the note conversion shares and warrant shares, while granting investors rights of first refusal, most-favored-nations terms and protections against variable-rate financings above a specified threshold.
In a concurrent April 21, 2026 press announcement, NEXGEL disclosed that Sequence LifeScience led the financing with a $5.5 million strategic investment structured as a convertible note at a $0.60 conversion price with 50% warrant coverage at $0.80. Sequence will act as contract manufacturer for NEXGEL’s new BioNX Surgical division and collaborate on new product development, aligning manufacturing and commercialization resources around the expanded regenerative biomaterials platform.
The Celularity deal licenses and acquires six established regenerative biomaterial products, most with existing reimbursement, and supports three planned new 510(k) product filings in 2026, 2027 and 2028. NEXGEL launched BioNX Surgical as a dedicated division focused on advanced biomaterials for tendon repair, soft tissue reconstruction and bone regeneration, positioning the company as an emerging platform in regenerative medicine with expanded clinical and commercial reach.
NEXGEL stated that, on a pro forma basis, the transaction is expected to roughly triple its annual revenue to about $35 million and be immediately accretive to profitability due to attractive gross margins and established reimbursement for the acquired products. Management emphasized that the strengthened balance sheet, expanded product portfolio and Sequence partnership should enhance operating leverage as NEXGEL integrates the business, accelerates commercialization and scales its presence in regenerative biomaterials.
The most recent analyst rating on (NXGL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
Spark’s Take on NXGL Stock
According to Spark, TipRanks’ AI Analyst, NXGL is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and cash burn) and a bearish longer-term technical trend (trading below key moving averages). Offsetting factors include improving margins and earnings-call guidance toward breakeven, plus potentially transformative corporate events, though both depend on execution and financing.
To see Spark’s full report on NXGL stock, click here.
More about NexGel Inc
NEXGEL, Inc. is a Nasdaq-listed provider of healthcare, beauty and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogels for medical and consumer uses. Based in Langhorne, Pa., it manufactures electron-beam, cross-linked hydrogels and markets brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm and Silly George, while also serving as a strategic contract manufacturer for major consumer healthcare companies.
Sequence LifeScience is a global life sciences company focused on regenerative biologics, manufacturing and distributing high-quality human tissue products. It brings expertise in tissue banking, orthopedic innovation and quality systems, emphasizing ethical sourcing and production for patients and donors.
Celularity Inc. is a regenerative and cellular medicine company whose commercial-stage regenerative biomaterials portfolio has now been licensed and partially acquired by NEXGEL. The transferred business includes established products used for tendon repair, soft tissue reconstruction and bone regeneration, many of which already benefit from insurance reimbursement pathways.
Average Trading Volume: 282,190
Technical Sentiment Signal: Sell
Current Market Cap: $8.36M
See more data about NXGL stock on TipRanks’ Stock Analysis page.